Cho-chin Cheng
Munich, BY, Germany
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
SARS-CoV-2 Productively Infects Human Hepatocytes and Induces Cell Death.
Journal: Journal of medical virology
Published: July 02, 2024
SARS-CoV-2 Neutralization Capacity in Hemodialysis Patients with and without a Fifth Vaccination with the Updated Comirnaty Original/Omicron BA.4-5 Vaccine.
Journal: Vaccines
Published: February 09, 2024
HBV-related HCC development in mice is STAT3 dependent and indicates an oncogenic effect of HBx.
Journal: JHEP reports : innovation in hepatology
Published: December 03, 2023
Longitudinal SARS-CoV-2 neutralization of Omicron BA.1, BA.5 and BQ.1.1 after four vaccinations and the impact of breakthrough infections in haemodialysis patients.
Journal: Clinical kidney journal
Published: March 13, 2023
Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients.
Journal: Frontiers in immunology
Published: February 23, 2023
Trimannose-coupled antimiR-21 for macrophage-targeted inhalation treatment of acute inflammatory lung damage.
Journal: Nature communications
Published: December 23, 2022
Improved SARS-CoV-2 Neutralization of Delta and Omicron BA.1 Variants of Concern after Fourth Vaccination in Hemodialysis Patients.
Journal: Vaccines
Published: July 20, 2022
Dynamics of humoral and cellular immune responses after homologous and heterologous SARS-CoV-2 vaccination with ChAdOx1 nCoV-19 and BNT162b2.
Journal: EBioMedicine
Published: March 22, 2022
Inhibition of SARS-CoV-2 replication in the lung with siRNA/VIPER polyplexes.
Journal: Journal of controlled release : official journal of the Controlled Release Society
Published: January 15, 2022
Three exposures to the spike protein of SARS-CoV-2 by either infection or vaccination elicit superior neutralizing immunity to all variants of concern.
Journal: Nature medicine
Published: January 03, 2022
Montelukast is a dual-purpose inhibitor of SARS-CoV-2 infection and virus-induced IL-6 expression identified by structure-based drug repurposing.
Journal: Computational and structural biotechnology journal
Published: September 25, 2021
Last Updated: 09/26/2026